From 2,000+ patients · Tirzepatide is already seeing results
Tirzepatide is the active ingredient in an FDA-approved GLP-1 receptor agonist for chronic weight management. Weight Method offers compounded Tirzepatide, prescribed by licensed providers, starting at $199/month with direct shipping.
Key Fact
Tirzepatide is a dual GIP/GLP-1 receptor agonist that activates both GIP and GLP-1 receptors. Weight Method's compounded tirzepatide program is dispensed by U.S.-licensed 503A compounding pharmacies starting at $329/month. Compounded tirzepatide is not FDA-approved.
Source: Weight Method clinical team
How does Tirzepatide work for weight loss?
Tirzepatide activates both GIP and GLP-1 receptors simultaneously to reduce appetite and slow gastric emptying. Compounded tirzepatide is not FDA-approved.
Tirzepatide works through a dual-agonist mechanism, activating both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. While GLP-1 suppresses appetite and slows gastric emptying, GIP affects fat metabolism and how your body processes and stores energy. This combined effect helps reduce hunger, support insulin sensitivity, and promote fat loss.
What is the Tirzepatide dosing schedule?
Start at 2.5mg weekly for 4 weeks, increase to 5mg, then escalate in 2.5mg increments monthly up to a maximum of 15mg.
Tirzepatide follows a carefully structured dose-escalation schedule to optimize tolerability. Treatment begins at 2.5mg once weekly for the first four weeks, then increases to 5mg for the next four weeks. After that, your provider may increase your dose in 2.5mg increments every four weeks -- progressing through 7.5mg, 10mg, 12.5mg, and up to a maximum of 15mg -- depending on your response and tolerance. Most patients find their optimal maintenance dose between 10mg and 15mg. Your Weight Method provider will tailor the escalation timeline to your individual progress and comfort level.
What are the common side effects of Tirzepatide?
Common side effects include nausea, diarrhea, decreased appetite, and mild injection site reactions, typically subsiding as the body adjusts to treatment.
The most common side effects of tirzepatide are gastrointestinal, including nausea, diarrhea, decreased appetite, vomiting, constipation, and injection site reactions such as mild redness or itching. These side effects are most frequent during the initial weeks and after dose increases, and they typically diminish as your body adapts. The slow dose-escalation protocol is specifically designed to reduce GI discomfort. Rare but serious side effects may include pancreatitis, gastroparesis, and allergic reactions; your Weight Method provider will assess your full health profile before prescribing tirzepatide.
Who qualifies for Tirzepatide treatment?
Adults with BMI ≥30, or BMI ≥27 with weight-related conditions. Your provider determines whether tirzepatide is an appropriate option based on your clinical profile.
You may be a candidate for tirzepatide if you have a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related comorbidity such as type 2 diabetes, obstructive sleep apnea, or cardiovascular disease. Tirzepatide is often recommended for patients seeking more aggressive weight loss or those who have not achieved sufficient results with other GLP-1 medications. You must be 18 or older and not pregnant, planning pregnancy, or breastfeeding. A history of medullary thyroid carcinoma or MEN 2 is a contraindication. Weight Method's free quiz helps determine if tirzepatide is the right fit based on your BMI, health history, and goals.
